Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maintenance therapy for superficial bladder cancer.

E C Baselli1, R E Greenberg

  • 1Department of Urology, Temple University Hospital, Philadelphia, Pennsylvania, USA.

Oncology (Williston Park, N.Y.)
|March 29, 2001
PubMed
Summary

Transurethral resection is standard for bladder cancer. Intravesical therapies like Bacillus Calmette-Guérin and mitomycin are effective in preventing recurrence and progression of superficial bladder tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment.

Brachytherapy·2014
Same author

Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer.

BJU international·2004
Same author

IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9-12, 2001.

Lung cancer (Amsterdam, Netherlands)·2002
Same author

Hypoxia in human prostate carcinoma: an Eppendorf PO2 study.

American journal of clinical oncology·2001
Same author

Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer.

Urology·2001
Same author

Loss of chromosomes 1 and X in a renal oncocytoma: implications for a possible pseudoautosomal tumor suppressor locus.

Cancer genetics and cytogenetics·2001

Area of Science:

  • Urology
  • Oncology

Background:

  • Transurethral resection is the primary treatment for transitional cell carcinoma of the bladder, crucial for staging.
  • Superficial bladder cancer patients often require adjunct intravesical therapy to prevent recurrence and progression.

Purpose of the Study:

  • To review traditional intravesical agents for superficial bladder cancer therapy and prophylaxis.
  • To discuss the long-term efficacy of these agents as maintenance therapy for high-risk patients.

Main Methods:

  • Review of existing literature on intravesical pharmacotherapy for bladder cancer.
  • Analysis of efficacy data for agents like Bacillus Calmette-Guérin and mitomycin.

Main Results:

  • Intravesical cytotoxic and immunomodulating agents are effective against superficial transitional cell carcinoma.
  • Bacillus Calmette-Guérin and mitomycin are commonly used and effective for prophylaxis against recurrence and progression.

Conclusions:

  • Intravesical therapy is a vital component in managing superficial bladder cancer.
  • Maintenance therapy with agents like Bacillus Calmette-Guérin and mitomycin shows long-term efficacy in higher-risk patients.

Related Experiment Videos